Datopotamab deruxtecan
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFRm Advanced Non-Small Cell Lung Cancer
Conditions
EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer
Trial Timeline
— → —
NCT ID
NCT06279728About Datopotamab deruxtecan
Datopotamab deruxtecan is a pre-clinical stage product being developed by Daiichi Sankyo for EGFRm Advanced Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06279728. Target conditions include EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06279728 | Pre-clinical | Completed |
| NCT06676917 | Phase 2 | Withdrawn |
| NCT06176261 | Phase 2 | Recruiting |
| NCT05866432 | Phase 2 | Recruiting |
Competing Products
3 competing products in EGFRm Advanced Non-Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Osimertinib-based adaptive treatment + Osimertinib 80 MG | AstraZeneca | Phase 2 | 52 |
| Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed | Roche | Phase 2 | 52 |
| PF-06459988 | Pfizer | Phase 2 | 51 |